Divi's Laboratories Q2 profit surges 64% to Rs 1,127 crore
- Net profit increased 64% to Rs 1,127 crore.
- Revenue grew 35% to reach Rs 27.15 billion.
- EBITDA margins expanded significantly to 42.6%.
- Market capitalization stands at Rs 1.66 Lakh crore.
- Share price closed at Rs 10,320.50 on November 7, 2026.
Divi's Laboratories reported a 64% increase in net profit to ₹1,127 crore for the second quarter of fiscal 2026-27, compared to ₹689 crore in the same period last year. Divi's Laboratories reported a 64% increase in net profit to ₹1,127 crore for the second quarter of fiscal 2026-27, compared to ₹689 crore in the same period last year.
The NIFTY50 index rose 10.2% to reach 25,030.35 points on November 6, 2026. During the same seven-day period, the BSE SENSEX index gained 10.6% to hit 81,028.02 points.
Revenue rises 35% to Rs 27.15 billion
Divi's Laboratories reported that its revenue for the second quarter of 2026 rose by 35% to reach Rs 27.15 billion.
EBITDA margins expand to 42.6%
The company experienced an expansion in its margins during the second quarter of 2026.
The EBITDA margin for Divi's Laboratories expanded to 42.6% in Q2 from 32.7% in the previous year.
Breakdown of tax, forex, and other income
Tax expense for the company was Rs 378 crore in Q2, compared to Rs 223 crore in the same period last year.
Stock performance and market valuation
Divi's Laboratories shares closed at Rs 10,320.50 on the National Stock Exchange on Friday, November 7, 2026, marking a 1.78% increase.
The company maintains a market capitalization of Rs 1.66 lakh crore and a price-to-earnings ratio of 133.11.
Publicly traded under the ticker symbols DIVISLAB.NS on the National Stock Exchange and DIVISLAB on the Bombay Stock Exchange, the company has been listed since its initial public offering on March 13, 2003. Market momentum was driven by strong Q2 corporate earnings, IPO listings such as Jio Platforms, the US midterm election victory for the Democrats, and significant FII buying support.
Company profile as an API manufacturer
Headquartered in Hyderabad, Telangana, Divi's Laboratories operates as a manufacturer of active pharmaceutical ingredients. The company produces generic active pharmaceutical ingredients, intermediates, and nutraceutical ingredients for clients across more than 100 countries. The firm provides custom synthesis of active pharmaceutical ingredients for large pharmaceutical companies.
Market context for November 2026
Market observers included Divi's Laboratories on a watchlist for November 7, 2026, with a specific focus on the company's export demand and EBITDA margins. Broader market sentiment has been positive, with the Sensex rising 1,609.54 points to 78,910.94 and the Nifty50 gaining 417.45 points to 24,378.05 on November 5, 2026. This movement added over Rs 6.9 lakh crore to investor wealth.
On November 4, 2026, the Sensex rose 383.55 points to 77,301.40, while the Nifty climbed 149.75 points to 23,960.60. The previous day, November 3, 2026, saw the Sensex increase by 1,225.07 points to 76,917.85 and the Nifty rise by 370.05 points to 23,810.85.
Market gains were also recorded on November 2, 2026, as the Sensex rose 1.66% to 75,692.78 and the Nifty increased 1.68% to 23,440.80. On November 2, 2026, Reliance Industries shares reached an intraday high of ₹1,259, rising 8.1% and pushing its market capitalization over ₹17 lakh crore.
Frequently Asked Questions
- Divi's Laboratories (tavily.com)
- Instagram (instagram.com)
- Companies, Earnings Archives | India Infoline (indiainfoline.com)
- NIFTY50 gains 7.6%, SENSEX up 5,755 points after sixth consecutive days of rally; will NIFTY be able to hit 25,000? (upstox.com)
- Why Is Nifty Rising/Falling Today (6th November 2026)? Key Market Drivers (anandrathi.com)
- Divi's Laboratories Q2 Results: Net Profit Jumps 64% To Rs 1,127 Crore, Revenue Rises 35%; Margins Expand (ndtvprofit.com)
Add NewsPulse Time as a preferred source on Google